Description
BSE informs trading members that 4,477,612 new equity shares of Suven Life Sciences Ltd are listed and permitted to trade effective February 26, 2026, issued on a preferential basis pursuant to conversion of warrants.
Summary
BSE Notice No. 20260225-21 informs trading members that 4,477,612 new equity shares of Suven Life Sciences Ltd (Scrip Code: 530239) have been listed and are permitted to trade on BSE with effect from Thursday, February 26, 2026. The shares were issued to Non-Promoters on a preferential basis pursuant to the conversion of warrants at an issue price of Rs. 134.00 per share.
Key Points
- Company: Suven Life Sciences Ltd (Scrip Code: 530239)
- Number of Shares: 4,477,612 equity shares of Rs. 1.00/- each
- Issue Price: Rs. 134.00/- per share (face value Rs. 1.00 + premium of Rs. 133.00)
- Issued To: Non-Promoters on a preferential basis via conversion of warrants
- Pari-Passu: Shares rank pari-passu with existing equity shares
- Distinctive Numbers: 227474208 to 231951819
- ISIN: INE495B01038
- Trading Effective From: February 26, 2026
Regulatory Changes
No new regulatory changes introduced. This is a standard listing notice under BSE’s procedures for permitting newly allotted securities to trade on the exchange.
Compliance Requirements
- Trading members are informed of the new securities and may facilitate trades from February 26, 2026 onwards.
- The lock-in restriction must be observed: all 4,477,612 shares (Dist. Nos. 227474208 to 231951819) are locked in until August 30, 2026 and cannot be traded until that date.
Important Dates
| Event | Date |
|---|---|
| Date of Allotment | January 29, 2026 |
| Trading Permitted From | February 26, 2026 |
| Lock-in Expiry | August 30, 2026 |
Impact Assessment
The listing adds 4,477,612 new equity shares to the tradeable float of Suven Life Sciences Ltd, representing a modest dilution for existing shareholders. However, since all newly listed shares are subject to a lock-in until August 30, 2026, there is no immediate increase in freely tradeable supply. The impact on market price and liquidity is expected to be low in the short term due to the lock-in constraint. Post lock-in expiry, the release of these shares into the market could result in mild selling pressure depending on market conditions at that time.
Impact Justification
Routine listing of new equity shares via preferential allotment following warrant conversion; includes a lock-in period relevant to existing and prospective shareholders of Suven Life Sciences Ltd.